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Abstract. The Rho GTPase Rac1 is a multifunctional 
protein working through different effector pathways. 
The emerging physiological significance of glycan-
lectin recognition gives reason to testing the possibil-
ity for an influence of modulation of Rac1 expression 
on these molecular aspects. Using human colon ade-
nocarcinoma (SW620) cells genetically engineered 
for its up- and down-regulation (Rac1+ and Rac1– 
cells) along with wild-type and mock-transfected 
control cells, the questions are addressed whether 
the presence of adhesion/growth-regulatory galec-
tins and distinct aspects of cell surface glycosylation 
are affected. Proceeding from RT-PCR data to 
Western blotting after two-dimensional gel electro-
phoresis and flow cytofluorimetry with non-crossre-
active antibodies against six members of this lectin 
family (i.e. galectins-1, -3, -4, -7, -8 and -9), a reduced 
extent of the presence of galectins-1, -7 and -9 was 
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revealed in the case of Rac1– cells. Application of 
these six galectins as probes to determination of cell 
reactivity for human lectins yielded relative increases 
in surface labelling of Rac1– cells with galectins-1, -3 
and -7. Examining distinct aspects of cell surface gly-
cosylation with a panel of 14 plant/fungal lectins dis-
closed a decrease in α2,6-sialylation of N-glycans and 
an increase in PNA-reactive sites (i.e. non-sialylated 
core 1 O-glycans), two alterations known to favour 
reactivity for galectins-1 and -3. Thus, manipulation 
of Rac1 expression selectively affects the expression 
pattern within the galectin network at the level of 
proteins and distinct aspects of cell surface glyco-
sylation.
Introduction
The members of the Rho family of GTPases (Rac, 
Rho	and	Cdc42)	are	molecular	switches	regulating	key	
cellular	activities,	among	them	apoptosis/cell	cycle	pro-
gression and directional movements by cytoskeleton re-
modelling	(Wherlock	and	Mellor,	2002;	Jaffe	and	Hall,	
2005;	Heasman	and	Ridley,	2008).	Involving	the	down-
stream	effectors	p21-activated	kinases	and	c-Jun	amino-
terminal kinases as well as transcription factors (e.g. 
nuclear	factor-κB),	a	Rho	protein	such	as	Rac1	can	also	
affect	gene	expression	(Coso	et	al.,	1995;	Perona	et	al.,	
1997;	Montaner	et	al.,	1998;	Burridge	and	Wennerberg,	
2004;	 Heasman	 and	 Ridley,	 2008;	 Machesky	 and	
Sansom,	2012).	Owing	to	the	emerging	significance	of	
Rac1 in clinically relevant processes, e.g. wound heal-
ing	 (its	engineered	deficiency	 impairing	myofibroblast	
formation and delaying cutaneous wound closure (Liu 
et	 al.,	 2009))	 or	 melanoma	 occurrence	 (Hodis	 et	 al.,	
2012;	Krauthammer	et	al.,	2012; for general review on 
malignancy,	please	see	Gómez	del	Pulgar	et	al.,	2005),	
delineating	the	routes	to	reach	the	specific	end	point	of	
interest poses an attractive challenge with promising 
therapeutic perspective. 
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Focusing on colorectal carcinoma, genetically engi-
neering Rac1 levels in human colon adenocarcinoma 
(SW620)	cells	combined	with	mRNA	array	analysis	of	
1423	genes	 identified	five	 types	of	 transcript	differen-
tially	 regulated	at	P	<	0.0002	when	comparing	 the	ef-
fects of Rac1 silencing/over-expression,	especially	two	
target genes of Wnt signalling (i.e. NKD1 and S100A4)	
(Gómez	del	Pulgar	et	al.,	2007).	Since	measuring	tumo-
rigenicity and mortality after orthotopic injection of sta-
bly	 modified	 lines	 into	 nude	 mice	 revealed	 increased	
Rac1	expression	to	enhance	progression	(Espina	et	al.,	
2008),	detailed	inspection	of	each	of	the	markedly	Rac1-
regulated genes is warranted, prompting us to take the 
detected transcriptional regulation of the glycogene 
among this set to the level of protein presence and cell 
surface presentation. Here we present the follow-up 
analysis	for	galectin-1	(Gal-1;	P	=	0.00016),	a	member	
of a family of adhesion/growth-regulatory lectins 
(Kaltner	and	Gabius,	2012).	These	proteins,	by	virtue	of	
their capacity to bind distinct carbohydrate determi-
nants, are able to translate information encoded in the 
glycan chains of cellular glycoconjugates into effects 
(for recent reviews on different aspects of the sugar 
code,	 please	 see	Gabius,	 2009;	 for	 an	 introduction	 to	
glycopathology,	please	 see	Gabius	and	Kayser,	2014).	
In view of the growing awareness of the physiological 
potential	 of	 orchestrating	 lectin-glycan	 expression	we	
examined	this	lectin	family	and	the	possibility	of	Rac1-
dependent alteration of the cellular glycophenotype.
Gal-1	 is	 a	 multifunctional	 protein	 with	 context-de-
pendent	activities	inside	(nucleus,	cytoplasm)	and	out-
side	 (surface,	 matrix)	 cells	 (Smetana	 et	 al.,	 2013).	
Nuclear localization and interaction with small nuclear 
ribonucleoprotein particles implicates the lectin in splic-
ing	(Haudek	et	al.,	2010;	Kodet	et	al.,	2011).	Its	cyto-
plasmic rendez-vous with oncogenic H-Ras ensures its 
routing as well as enhanced and prolonged Raf1 and 
mitogen-activated protein kinase stimulation (Elad- 
-Sfadia	et	al.,	2002;	Rotblat	et	al.,	2004; Villalobo et al., 
2006).	As	a	glycan-binding	cell	surface	effector,	it	can	
trigger	signalling	to	induce	p21/p27-dependent	cell	cy-
cle	 arrest	 or	 caspase-8-mediated	 anoikis	 in	 carcinoma	
cells	(Fischer	et	al.,	2005;	André	et	al.,	2007; Sanchez- 
-Ruderisch	et	al.,	2011),	affect	cell	motility	and	invasion	
depending	on	the	tumour	cell	type	(Camby	et	al.,	2002; 
Hittelet	et	al.,	2003;	Roda	et	al.,	2009)	and	convert	fibro-
blasts	to	myofibroblasts	nourishing	a	tumour-promoting	
microenvironment	(Dvořánková	et	al.,	2011; Valach et 
al.,	2012).	Having	mentioned	the	role	of	Rac1	in	wound	
healing above, the Gal-1 presence and tissue reactivity 
to lectin were found to undergo changes during progres-
sion of this process analysed for skin and trachea (Gál et 
al.,	2011;	Grendel	et	al.,	2012).	
The	SW620	cells	studied	here	are	known	to	express	
Gal-1 and other members of the galectin family, which 
are also present in colon carcinomas in vivo (André et 
al.,	1999;	Lahm	et	al.,	2001;	Nagy	et	al.,	2003; Saal et 
al.,	2005;	Gebert	et	al.,	2012;	Dawson	et	al.,	2013).	In	
addition to Gal-1 monitoring by RT-PCR, two-dimen-
sional	gel	electrophoresis	and	flow	cytofluorimetry,	the	
evidence for a network gave reason to similarly study 
galectins-2,	-3,	-4,	-7,	-8	and	-9.	Considering	their	extra-
cellular functionality by targeting certain glycoconju-
gates (glycolipids such as ganglioside GM1 or sulpha-
tide,	 glycoproteins	 such	 as	 fibronectin	 or	 its	 receptor,	
α5β1-integrin)	as	counterreceptors,	we	then	obtained	in-
formation	on	the	extent	of	cell	reactivity	to	galectins	by	
assessing the cells’ capacity to bind Gal-1 and the other 
listed	 family	 members	 using	 flow	 cytofluorimetry.	
Hereby, galectin-relevant aspects of the cell surface gly-
come were quantitatively characterized. To broaden the 
comparative	glycophenotyping,	14	plant/fungal lectins 
were similarly used as sensors to trace the Rac1-de-
pendent impact on cell surface glycosylation (for an in-
troduction to N- and O-glycosylation, please see Patsos 
and	 Corfield,	 2009;	 Zuber	 and	 Roth,	 2009).	 Of	 note,	
such changes are not only known to be able to modulate 
reactivity to endogenous lectins, but also glycoprotein 
functions	and	even	their	trafficking/stability	(Gabius	et	
al.,	 2011,	 2012).	 Our	 experiments	 therefore	 took	 the	
previously noted Rac1 effects on gene transcription for 
Gal-1 to the level of the protein presence and beyond 
Gal-1 in this family of lectins. Moreover, they led to 
revealing changes in N- and mucin-type O-glycan sia-
lylation, adding at least three galectins and two features 
of cell surface glycosylation to the list of cellular targets 
of Rac1.
Material and Methods
Cell culture 
Human	 colon	 adenocarcinoma	 (SW620)	 cells	 were	
cultured	in	RPMI	1640	medium	(Sigma,	Munich,	Ger-
many)	supplemented	with	10%	foetal	calf	serum	(Bio-
chrom,	Berlin,	Germany),	2	mM	L-glutamine, 100 U/ml 
penicillin and 100 mg/ml streptomycin. Mock transfec-
tion	was	performed	using	the	pcDNA3.1	vector	without	
the galectin-encoding cDNA insert (Invitrogen, Karl-
sruhe,	Germany),	setting	a	concentration	of	1	mg/ml of 
neomycin	 (G418;	 Roth,	 Karlsruhe,	 Germany)	 during	
selection,	 lowered	 to	200	mg/ml for routine culture of 
cell	 clones,	 as	described	 for	 the	Rac1-over-expressing	
clone (Rac1+)	and	 the	clone	carrying	 the	short	hairpin	
RNA against human rac1 (Rac1-)	(Gómez	del	Pulgar	et	
al.,	2007).
RNA extraction and RT-PCR profiling
Total	 RNA	 from	 cell	 extracts	 was	 obtained	 by	
RNAeasy	 mini	 columns	 (Qiagen,	 Hilden,	 Germany),	
then checked for integrity by agarose gel electrophore-
sis, freed of any residual DNA contamination by treat-
ment with RNase-free DNase I (Roche Diagnostics, 
Mannheim,	Germany)	and	used	as	template	for	Super-
scriptTM II RNase H-	Reverse	Transcriptase	(Invitrogen)	
as	described	(Lohr	et	al.,	2007).	PCR	amplification	was	
directed	by	primer	sets	specific	for	human	galectins-1,	
-2,	 -3,	 -4,	 -7,	 -8	 and	 -9,	 respectively,	 using	Taq DNA 
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polymerase	 in	 30	 cycles	 as	 described	 (Lahm	 et	 al.,	
2001),	followed	by	gel	electrophoresis	in	2%	agarose	at	
40	V	for	80	min	and	visualization	of	bands.
Two-dimensional gel electrophoresis and 
Western blot-based galectin detection 
Samples	of	extracted	protein	were	prepared	and	pro-
cessed	 by	 isoelectric	 focusing	 (pI	 range:	 3-10)	 in	 an	
IPGphorTM	unit	(GE	Healthcare,	Freiburg,	Germany)	at	
about	 42	 kVh,	 followed	 by	 further	 separation	 of	 the	
mixture	of	extract	(glyco)proteins	according	to	mobility	
in	 12.5%	 running	 gel	 using	 a	 Hoefer	 SE-600	 system	
(Hoefer,	Inc.,	Holliston,	MO),	fixation	of	gels	and	elec-
trotransfer	 of	 the	 (glyco)proteins	 to	 nitrocellulose	 as	
	described	(Purkrábková	et	al.,	2003).	Galectin	identifi-
cation was accomplished with non-crossreactive poly-
clonal anti-galectin antibodies, obtained by in-house 
production combined with chromatographic removal of 
fractions from each immunoglobulin G preparation that 
were	cross-reactive	with	a	second	(or	more)	member(s)	
of the family, at a concentration of 1 mg/ml when using 
recombinant	galectins	 (3-6	ng)	or	 400	mg protein per 
extract	 sample	 and	 a	 goat	 anti-rabbit	 immunoglobulin	
G-horseradish	peroxidase	conjugate	(0.5	mg/ml;	Sigma)	
by enhanced chemiluminescence detection, driven by a 
substrate	mixture	with	1.25	mM	sodium	salt	of	luminol	
in	2	ml	0.1	M	Tris-HCl	(pH	8.6),	0.2	ml	6.7	mM	p-cou-
maric	acid	in	dimethyl	sulphoxide	and	0.6	ml H2O2	(30%	
v/v)	for	2	min	at	room	temperature.	Exposure	periods	of	
the processed blot to CL-XPosureTM	X-ray	film	(Pierce,	
Bonn,	Germany)	were	routinely	set	to	8	minutes.
Flow cytofluorimetric cell surface analyses
Quantitation of cell surface presentation of galectins 
was performed in a FACScan instrument (Becton-
Dickinson,	Heidelberg,	Germany)	with	suspension	sam-
ples	of	4×105 cells. Labelling for immunodetection was 
performed with solutions containing non-crossreactive 
anti-galectin antibodies (10 mg/ml)	as	first-step	reagents	
and	fluorescein	thiocarbamyl-labelled	conjugate	of	goat	
anti-rabbit	 immunoglobulin	 G	 (Sigma)	 as	 described	
(André	 et	 al.,	 1999,	 2007).	 Biotinylated	 plant	 lectins	
(PHA-E, PHA-L, LEA, SNA, DBA, MAA-I, PNA, ja-
calin	 and	 UEA-I)	 were	 from	Alexis	 (Grünberg,	 Ger-
many),	biotinylated	 lectins	 from	Canavalia ensiformis 
(ConA),	Lens culinaris	 (LCA),	Pisum sativum	 (PSA),	
Polyporus squamosus	(PSL)	and	Viscum album (VAA)	
and biotinylated/fluorescent	 galectins	 were	 prepared	
and	 tested	 for	maintained	sugar	 specificity	by	a	 solid-
phase	assay	using	(neo)glycoconjugates	 for	matrix	es-
tablishment and cytochemical staining of specimens 
with	known	reactivity	as	described	(André	et	al.,	2003,	
2011;	 Habermann	 et	 al.,	 2011; Schlötzer-Schrehardt 
et	al.,	 2012).	 Fluorescent	 streptavidin/R-phycoerythrin 
conjugate	(1 : 40;	Sigma)	was	used	for	detection	of	cell-
bound biotin, controls for carbohydrate-dependent bind-
ing and titrations to reach saturation were routinely per-
formed	as	described	(Kopitz	et	al.,	2013).	
Results
From RT-PCR profiling of galectin gene 
expression to cell surface presentation 
of galectins
The pattern of mRNA presence in the galectin net-
work was determined with a set of seven galectin-type-
specific	primers	pairs.	Confirming	previous	monitoring	
of	the	SW620	(wild-type)	cell	line	(Lahm	et	al.,	2001),	
transcription of galectin genes goes beyond the most of-
ten	studied	genes	 for	Gal-1	and	-3	 (Fig.	1).	Lack	of	a	
signal	in	the	case	of	Gal-2	in	all	four	cell	preparations	
gives	an	example	 for	qualitatively	different	 regulation	
within this lectin family. The mock-transfected cells 
presented the same pattern as the wild-type cells, as did 
the Rac1+	 cells	 (Fig.	1).	 In	comparison,	drastic	differ-
ences	 in	 expression	 of	 the	 genes	 for	Gal-1,	 -7	 and	 -9	
were	 detectable	 after	 30	 cycles	when	 testing	material	
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Fig. 1.	Profiling	of	the	extent	of	mRNA	presence	from	tran-
scription of galectin genes in the colon adenocarcinoma 
(SW620)	wild-type	cells	and	their	variants.	The	main	band	
in	 each	 lane	 represents	 the	 amplification	 product	 from	
RT-PCR	using	galectin-type-specific	primer	sets,	consist-
ently occurring at the position predicted for the respective 
cDNA.	Amplification	of	β-actin-specific	cDNA	served	as	a	
loading and quality control. Calibration for length is given 
for 500 bp and 1000 bp by arrowheads.
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from Rac1- cells	(Fig.	1).	Evidently,	the	microarray	data	
on gal1 gene transcription (Gómez del Pulgar et al., 
2007)	 were	 reflected	 in	 the	 RT-PCR	 analysis.	What’s	
more,	these	experiments	revealed	an	effect	of	silencing	
Rac1	 expression	 posttranscriptionally	 on	 the	 relative	
abundance	of	mRNA	presence	for	Gal-7	and	-9.	To	what	
extent	proteins	were	detectable	in	cell	extracts	was	ex-
amined by two-dimensional gel electrophoresis com-
bined with Western blot-based detection, with recombi-
nant proteins as controls. 
At the level of protein, data from Western blotting 
were fully in line with a marked reduction of the Gal-1 
presence. The main spot of human Gal-1 and additional 
variants separated by isoelectric focusing were seen af-
ter	 extract	 processing	 of	 cells	 (wild-type,	mock-trans-
fected and Rac1+)	at	rather	similar	intensity	under	iden-
tical	 conditions,	 whereas	 prolonged	 exposure	 times	
were required for recording the chemiluminescence sig-
nal	when	testing	the	same	quantity	of	extracted	protein	
from Rac1- cells	(Fig.	2,	left	panel).	In	contrast,	extents	
of	 Gal-3	 presence	 (the	 main	 spot	 is	 protein	 without	
phosphorylation, the minor spot at lower pI value pro-
tein	with	Ser	phosphorylation;	please	see	Hamann	et	al.,	
1991	 for	 its	 detection	 in	 human	SL66	fibroblasts)	 ap-
peared rather similar for all cell types, similarly as the 
respective	RT-PCR	signals	(Fig.	2,	right	panel).	Main-
taining identical conditions, no respective signal for 
phosphorylation	of	Gal-3	 in	Rac1- cells was recorded. 
Performing the immunodetection protocol after Western 
blotting	for	Gal-4,	 -7,	 -8	and	-9	consistently	disclosed	
medium	 to	weak	 signals	 for	Gal-8	 and	Gal-4,	 respec-
tively,	a	marked	difference	in	the	case	of	Gal-7,	as	seen	
for	Gal-1,	and	a	slight	difference	for	Gal-9,	with	Rac1- 
cells harbouring less galectin than the other cell prepara-
tions	(not	shown).	
When looking at the cell surface presentation of ga-
lectin	by	cytofluorimetry,	special	care	was	exercised	to	
monitoring	all	four	types	of	SW620	cells	with	aliquots	
of the same antibody-containing solutions under identi-
cal culture parameters, analysing the suspensions always 
in parallel, each cell batch repeatedly and several prepa-
rations from different cell stocks, this to ensure repro-
ducibility within the limits of accuracy of the method. 
The	availability	of	non-crossreactive	antibodies	exclud-
ed ambiguities in interpretation of signals. Titrations of 
antibody concentration were done for each galectin and 
cell	type	to	find	out	the	linear	range	for	the	relationship	
of	 antibody	 concentration	 to	 the	 extent	 of	 positivity,	
where comparative measurements will be most sensitive 
for spotting differences. 
The assessment of quantitative data on the Gal-1 cell 
surface presence broadened the range of the impact of 
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Fig. 2. Protein pattern after two-dimensional gel electro-
phoretic analysis combined with Western blot-based detec-
tion	of	recombinant	human	galectins	(Gal-1	at	3	ng,	Gal-3	
at	6	ng)	and	their	presence	in	extracts	(400	µg	protein)	of	
wild-type	 (WT),	 mock-transfected	 (Mock),	 Rac1+ and 
Rac1–	cells.	Inset:	exposure	time	extended	from	routinely	
used	8	to	16	min	to	trace	positivity.
Fig. 3. Cytofluorimetric	analysis	of	cell	surface	presenta-
tion	of	Gal-1	(solid	line)	and	Gal-3	(dashed	line;	A-D)	as	
well	as	Gal-8	(dashed	line)	and	Gal-9	(solid	line;	E, F)	us-
ing	 a	 two-step	 procedure	with	 specific	 non-crossreactive	
polyclonal	 rabbit	 antibodies	 (10	 µg/ml)	 and	 fluorescent	
second-step	 (goat	 anti-rabbit)	 antibody.	 A, E:	 wild-type	
cells, B:	mock-transfected	wild-type	cells,	C:	Rac1+ cells, 
D, F:	Rac1– cells. Quantitative data on the percentage of 
positive	cells	and	mean	fluorescence	intensity	are	given	in	
each panel. The control value representing marker-inde-
pendent staining is given as shaded area.
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Rac1	silencing	on	this	parameter:	Gal-1	was	found	on	
the surface of Rac1- cells in a comparatively small quan-
tity	 (Fig.	 3A-D).	 The	 Gal-3-dependent	 signals	 were	
rather equal, with a tendency for up-regulation on Rac1- 
cells	 (Fig.	 3A-D).	 Whereas	 the	 surface	 presence	 of	
Gal-4	 and	 -7	 was	 barely	 tracked	 down,	 Gal-8	 and	 -9	
were	detectable,	 and	 this	with	differences.	Less	Gal-9	
but	more	Gal-8	was	 seen	 on	Rac1- cells	 (Fig.	 3E,	 F).	
Viewed from the perspective of a network, Rac1- cells 
were	delineated	to	have	lower	Gal-1	and	-9	cell	surface	
presence	 than	 the	 other	 SW620	 cell	 clones,	while	 the	
level	 of	 Gal-8	 appeared	 to	 be	 increased.	 Obviously,	
a decrease in the Rac1 presence has an impact on sev-
eral galectins. This effect was seen on the levels of total 
protein	 (Western	 blot)	 and	 surface	 presentation	 (cyto-
fluorimetry),	 the	 latter	 parameter	 relevant	 for	 glycan-
dependent activities in cell death, invasion or migration. 
In order to trigger respective signalling cascades, suited 
cell surface glycans that act as counterreceptors for ga-
lectins will be essential. This prerequisite prompted us 
to perform glycophenotyping with human galectins as 
a tool. Cell positivity was assumed to be a measure of 
reactivity	to	galectin	exposure.	The	panel	of	probes	to-
wards	this	end	was	extended	from	galectins	by	14	plant	
and fungal lectins. They were selected for their capacity 
to monitor distinct aspects of glycosylation. 
Glycophenotyping of cell surfaces by human 
and plant/fungal lectins
Routinely, comparative monitoring started with 
measuring the concentration dependence of surface 
staining and the effect of cognate sugar on signal gen-
eration,	as	illustrated	for	a	galectin	(Gal-3)	and	a	plant	
lectin	(VAA)	in	Fig.	4.	The	presence	of	haptenic	sugar	
nearly completely blocked binding, ascertaining the as-
sumed	carbohydrate	dependence	of	binding.	To	exclude	
an	osmolarity	effect	by	the	sugar	presence,	parallel	ex-
periments	with	20	mM	mannose	(in	 these	cases)	were	
performed, with no effect on staining. As usual in cyto-
fluorimetry,	binding	data	were	reported	as	percentage	of	
positive cells/mean	 fluorescence	 intensity,	 these	 num-
bers	 inserted	to	each	panel	of	respective	figures	(Figs.	
4-7).	For	each	lectin,	assays	were	carried	out	simultane-
ously with aliquots of lectin-containing solutions (at the 
same	concentration)	and	of	cell	 suspensions,	 for	com-
parison of at least two lectin concentrations below the 
saturation level. Sets of scans for the four cell types 
were	 thus	 obtained,	 as	 exemplarily	 documented	 for	
VAA in Fig. 5. Routinely, they were collected for the 
same culture batch at consecutive days and for several 
preparations of different cell stocks as noted above. In 
this	figure	(for	VAA),	a	higher	reactivity	of	Rac1- cells 
for	the	galactoside-specific	plant	lectin	was	consistently	
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Fig. 4.	Cytofluorimetric	analysis	of	cell	surface	staining	by	
labelled lectins (A, B:	Gal-3, C, D:	VAA).	The	control	val-
ue representing lectin-independent staining is given as 
shaded area, quantitative data on the percentage of positive 
cells/mean	 fluorescence	 intensity	 are	 presented	 for	 each	
scan	profile	in	the	order	of	listing	the	respective	series	of	
concentrations	(from	top	to	bottom).	A, C:	staining	param-
eters of Rac1– cells measured with increasing concentra-
tions	of	labelled	lectin	from	0.5	µg/ml	to	1	µg/ml,	2	µg/ml	
and	4	µg/ml;	B:	inhibition	of	Gal-3-dependent	staining	of	
wild-type	cells	by	lactose	concentrations	of	20	mM,	5	mM,	
2	mM,	1	mM	and	0.5	mM	(at	4	µg/ml	Gal-3);	D:	inhibition	
of VAA-dependent staining of Rac1– cells by lactose con-
centrations	of	20	mM,	5	mM,	2	mM	and	0.5	mM	(at	2	µg/ml	
VAA).	The	100%	values	(in	the	absence	of	inhibitor)	are	
printed in bold (B, D).
Fig. 5.	 Comparative	 cytofluorimetric	 analysis	 of	 surface	
staining	 by	 labelled	VAA	 (at	 2	 µg/ml)	 of	wild-type	 (A),	
mock-transfected wild-type (B),	Rac1+ (C)	and	Rac1– (D)	
cells	(scan	profile	for	Rac1– cells in panel D is part of the 
concentration	series	presented	in	Fig.	4C).
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detected than for the other three test lines (please note 
relatively	 higher	 background	 levels	 for	 mean	 fluores-
cence intensity in these lines relative to Rac1–	cells).	
Systematic application of labelled galectins to the 
four	types	of	SW620	cells	traced	differences.	Like	Gal-3,	
Gal-1	 (and	 also	Gal-7)	was	most	 reactive	with	Rac1- 
and least reactive with Rac1+	cells	(Fig.	6).	In	contrast,	
the	 binding	 profiles	 for	 Gal-4,	 -8	 and	 -9	 were	 rather	
similar	 (not	 shown),	 indicating	non-uniform	 target	 se-
lection	on	SW620	cells	among	galectins.	Viewed	toget-
her with the data presented in Fig. 5 on VAA-de pendent 
staining,	increased	presentation	of	β-gala	cto	sides	reac-
tive	with	galectins-1,	-3	and	-7	characterized	Rac1- cells. 
Which	shifts	within	cell	surface	glycosylation	may	ex-
plain the increased galectin reactivity and whether other 
aspects of the glycome were altered was studied by an 
extension	of	the	panel	of	probes	from	human	galectins	
to	14	plant/fungal lectins. In detail, glycan characteris-
tics monitored were the N-glycan core (without/with 
core	 fucosylation)	 by	 ConA,	 PSA	 and	 LCA,	 the	 core	
substitution	by	bisecting	N-acetyl	glu	cosamine	(PHA-E),	
β1,6-branching	 (PHA-L),	 extension	 of	 branches	 by	
N-acetyllactosamine	 repeats	 (LEA),	 α2,3/6-sialylation	
(MAA-I,	 PSL,	 SNA),	 Tn	 antigen	 (DBA),	 mucin-type	
core 1 O-glycan disaccharide (without/with	sialylation)	
by	PNA	and	jacalin	as	well	as	histo-blood	group	H(O)	
fucosylation	(UEA-I).
The majority of the probes bound to the cells in a 
comparable manner. Tests were routinely run at differ-
ent lectin concentrations to protect us against missing a 
difference. These were reproducibly apparent in the 
comparative measurements for three lectins. As docu-
mented	in	Fig.	7A-J,	the	SW620	cell	types	differed	in	
α2,6-sialylation	 of	 N-glycans	 (independently	 detected	
by	two	probes	(PSL,	SNA)	and	excluding	a	contribution	
of clustered Tn antigen to SNA-dependent staining by 
measuring a low level of DBA reactivity in all four cell 
types;	please	see	Table	1	for	details	on	glycan	specifici-
ties	 of	 the	mentioned	 lectins)	 but	 not	 α2,3-sialylation	
(monitored	by	MAA-I,	also	by	Gal-8	mentioned	above).	
As	a	second	discriminatory	feature,	the	extent	of	presen-
tation	of	non-sialylated	core	1	(PNA-reactive)	disaccha-
ride	was	disparate.	The	extent	of	jacalin	staining,	an	in-
dicator for additional presence of sialylated core 1 
O-glycans	(Table	1),	was	uniform,	shown	for	Rac1+ and 
Rac1– cells	in	Fig.	7K,	L.	Evidently,	the	presence	of	ja-
calin-reactive core 1 O-glycans (the disaccharide and its 
α2,3-sialylated	 form)	 remained	 constant.	 Instead	 of	 a	
lack of effect or a general change in the glycome, modu-
lation of the Rac1 level by transfection led to alterations 
of	distinct	structural	features,	i.e.	α2,6-sialylation	of	
N-glycans and core 1 O-glycan disaccharide presence. 
Discussion
Our study was designed to answer the questions 
whether	modulating	the	Rac1	level	in	SW620	cells	will	
translate	into	effects	on	i)	the	protein	presence	for	adhe-
sion/growth-regulatory	Gal-1,	taking	the	next	step	after	
detecting the wide difference between Rac1+ and Rac1- 
cells by mRNA-based array analysis (Gómez del Pulgar 
et	al.,	2007),	and	for	other	members	of	 this	family,	 ii)	
the	surface	presentation	of	the	galectins	and	iii)	cell	sur-
face glycosylation. Indeed, marked down-regulation of 
Gal-1-specific	mRNA	presence,	confirmed	by	RT-PCR	
data, accounted for the lowered protein level measured 
by Western blotting. The obtained protein spots in two-
dimensional gel electrophoretic analysis formed the 
common pattern of variants with differences in the iso-
electric point known from human Gal-1 (Avellana-Ada-
lid	et	al.,	1992).	No	evidence	for	phosphorylation,	Gal-1	
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Fig. 6.	 Comparative	 cytofluorimetric	 analysis	 of	 surface	
staining	 by	 labelled	 Gal-3	 (A-D;	 at	 2	 µg/ml)	 and	Gal-1	
(E-H;	at	20	µg/ml)	of	wild-type	cells	(A, E),	mock-trans-
fected wild-type (B, F)	Rac1+ (C, G)	 and	Rac1– (D, H)	
cells	 (scan	profile	 for	Gal-3-dependent	 staining	of	Rac1– 
cells in panel D is part of the concentration series presented 
in	Fig.	4A).
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being a substrate for protein kinase CK1 (Kübler et al., 
2014),	was	obtained.	Regarding	this	type	of	post-trans-
lational	 galectin	modification,	Gal-3	 proved	 to	 be	 the	
only	positive	case.	Its	extent	of	phosphorylation,	which	
is	connected	to	recognition	processes	within	nuclear	ex-
port and association with distinct glycoproteins (Ha-
mann	et	al.,	1991;	Díez-Revuelta	et	al.,	2010),	was	re-
duced in Rac1– cells. 
Rac	1	Affects	Galectins/Glycosylation
Fig. 7.	Comparative	cytofluorimetric	analysis	of	surface	staining	by	labelled	PSL	(A-D;	at	0.25	µg/ml),	SNA	(E, F;	at	
5	µg/ml),	MAA-I	(G, H;	at	20	µg/ml),	PNA	(I, J;	at	10	µg/ml)	and	jacalin	(K, L;	at	5	µg/ml)	for	wild-type	(A, G),	mock-
-transfected wild-type (B),	Rac1+ (C, E, I, K)	and	Rac1– (D, F, H, J, L)	cells.
Table 1. Plant/fungal agglutinins of special relevance for glycophenotyping of SW620 wild-type cells and their transfectants
Species Abbreviation Monosaccharide 
specificity
Potent glycan ligands
Viscum album	(mistletoe) VAA Gal Galβ2(3)Gal,Galα3(4)Gal,	Galβ3(4)GlcNAc	without/with	
α2,6-sialylation,	Fucα2Gal
Polyporus squamosus 
(polypore	mushroom)
PSL a Neu5Acα6Galβ4Glc(NAc)	(over	300-fold	more	active	than	
LacNAc,	not	reactive	with	free	Neu5Ac);	6’-sulphation	
tolerated;	6’-sialyl	Tn not reactive
Sambucus nigra (elderberry)	 SNA Gal/GalNAc Neu5Ac/Gcα6Gal/GalNAcb;	9’-O-acetylation	tolerated;	
clustered Tn antigen
Dolichos biflorus (horse	gram) DBA GalNAc GalNAcα3GalNAcα3Galβ4Galβ4Glc;	clustered	Tn antigen
Maackia amurensis agglutinin-I 
(leukoagglutinin)
MAA-I a Neu5Ac/Gcα3Galβ4GlcNAc/Glcc;	3’-sulphation	instead	of	
sialylation	and	9’-O-acetylation	tolerated
Arachis hypogaea (peanut) PNA Gal Galβ3GalNAcα/β
Artocarpus integrifolia 
(jack	fruit)
jacalin	(JAC) Gal/GalNAc Galβ3GalNAcα;	sialylation	of	T/Tn antigens tolerated
a	no	monosaccharide	known	as	ligand;	b binding of type I LacNAc (Galb3GlcNAc)	core	preferred,	6’-sulphation	of	GlcNAc	in	
a2,6-sialylated	LacNAc	(type	I/II)	enhances	affinity	(Chokhawala	et	al.,	2008);	c	binding	specific	for	type	II	LacNAc	(Galb4GlcNAc)	
core	(Knibbs	et	al.,	1991)
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Flow	cytofluorimetry	took	the	characterization	of	ef-
fects to the level of the cell surface, where Gal-1 was 
much less present in Rac1- cells than in the other three 
cell forms. Beyond Gal-1, a decrease of the protein level 
was	also	detected	for	Gal-7	and	-9	(as	seen	in	RT-PCR	
analyses),	and	cell	surface	availability	also	lowered	for	
Gal-9	but	 increased	 for	Gal-8.	This	galectin	 is	known	
for reducing migration of colon cancer cells with low 
growth rate in vivo	 (HCT-15,	CoLo201)	 (Nagy	 et	 al.,	
2002).	Overall,	the	presented	set	of	results	underscores	
the	 importance	of	 extending	measurements	 from	 indi-
vidual family members to other constituents of the net-
work. In fact, the potential for functional antagonism/
synergy and for compensatory regulation upon an in-
duced loss, an idea inspiring a promising research route, 
calls	for	such	fingerprinting,	especially	if	not	all	galectin	
genes are represented on the arrays. Immuno histo-
chemically,	 galectin	fingerprinting	had	proved	 charac-
teristic	expression	profiles	for	 individual	galectins	and	
indicated diagnostic applicability, recently documented 
in head and neck tumours with focus on squamous epi-
thelium	(Čada	et	al.,	2009;	Cludts	et	al.,	2009; Saussez 
et	al.,	2009;	Remmelink	et	al.,	2011;	Fík	et	al.,	2013).	
Cell biologically, the tempting hypothesis for functional 
antagonism in growth regulation had been substantiated 
for	Gal-1	and	Gal-3,	the	chimera-type	protein	compet-
ing with Gal-1 for counterreceptor binding (Kopitz et 
al.,	2001;	Sanchez-Ruderisch	et	al.,	2010).	
Precedents for transcriptional regulation of gal1 or 
gal7	(also	called	p53-induced	gene	1),	respectively,	are	
given	 by	 the	 tumour	 suppressors	 p16INK4a	 and	 p53	
(Polyak	et	al.,	1997;	André	et	al.,	2007; Barkan et al., 
2013).	Of	note,	the	orchestration	of	galectin	expression	
by	 p16INK4a	 in	 pancreatic	 adenocarcinoma	 (Capan-1)	
cells, one factor to increase susceptibility for anoikis in-
duction, entailed reduction of stability of the anti-apop-
totic	 Gal-3	 protein	 (Sanchez-Ruderisch	 et	 al.,	 2010).	
Five lines of evidence have prompted us to proceed 
from looking at the galectin network to monitoring the 
cell	surface	glycophenotype	in	this	cell	system:	
	 i)	the	tumor	suppressor	p16INK4a, acting as master regu-
lator, not only reprograms the galectin availability 
(protein	presence,	cell	surface	presentation)	but	also	
directs remodelling of cell surface glycosylation by 
lowering sialic acid biosynthesis to make cells more 
reactive to Gal-1, hereby furthering its capacity to 
induce	 anoikis	 by	 α5β1-integrin cross-linking and 
caspase-8	activation	(André	et	al.,	2007; Amano et 
al.,	2012).	
	ii)	ectopic	expression	of	the	Rho	GTPase	oncogene	ras 
potently	induces	α2,6-sialyltransferase	expression	to	
enhance	α2,6-sialylation	in	fibroblasts	and	HD3	co-
lonocytes	 (Bolscher	 et	 al.,	 1988; Le Marer et al., 
1992;	Vandamme	 et	 al.,	 1992;	 Seales	 et	 al.,	 2003; 
Dalziel	et	al.,	2004).
	iii)	reconstitution	of	 the	status	of	 three	distinct	 tumour	
suppressors in a microsatellite-instable colon cancer 
cell	 line	 (HCT116),	 up-regulation	 of	 caveolin-1,	 a	
cell-context-dependent	 oncogene/suppressor, and 
Wnt signalling activation are documented to affect 
distinct aspects of the glycophenotype, prominently 
among	 them	 α2,6-sialylation	 (Patsos	 et	 al.,	 2009; 
Sengupta	et	al.,	2010;	Yu	et	al.,	2012).
	iv)	ensuing	changes	of	the	glycophenotype	such	as	alte-
red	 α2,6-sialylation	 of	 N-glycans	 (here	 β1-integrin 
has been shown to be among the targets, with impli-
cations for its cis/trans	activities;	for	review,	please	
see	Gu	et	al.,	2009)	make	their	presence	felt	in	cell	
biological assays, e.g. for colony formation, invasi-
veness,	 matrix	 attachment,	 and	 motility	 of	 colon	
cancer	and	epithelial	(SW48)	cells	(Dall’Olio	et	al.,	
1991;	Zhu	et	al.,	2001;	Seales	et	al.,	2005;	Shaikh	et	
al.,	2008).	
	v)	cell	 membrane	 staining	 of	 clinical	 specimens	 of	
advanced head and neck (oropharyngeal and laryn-
geal)	cancer	(stages	III/IV)	with	labelled	Gal-3	pro-
ved	 to	 be	 an	 independent	 (favourable)	 prognostic	
indicator	(P	=	0.026;	Plzák	et	al.,	2004).	
Our decision to focus on cell surface glycophenotyp-
ing	by	flow	cytofluorimetry	but	not	RT-PCR	or	microar-
ray	monitoring	of	glycogene	expression	was	based	on	
the	fact	that	SW620	cells	are	an	intriguing	case	for	the	
scenario that “an average level of enzyme activity (here 
α2,6-sialyltransferase)	is	supported	by	extremely	weak	
mRNA	expression”	(Dall’Olio	et	al.,	1999).	Moreover,	
the accessibility of glycan determinants to the probes 
indicates bio-availability, a prerequisite to serving as li-
gand in biorecognition. 
The	cytofluorimetric	monitoring	revealed	a	conspicu-
ous	 increase	 in	 cell	 reactivity	 to	 Gal-1,	 -3	 and	 -7	 in	
Rac1- relative to Rac1+ cells. On average, especially the 
percentage of positive cells went up in comparative 
measurements. However, cells did not become more re-
active to all tested galectins. Interestingly, the tandem-
repeat-type	Gal-4,	-8	and	-9	bound	to	cells	of	the	same	
preparation,	 assays	 run	 in	 parallel,	 in	 similar	 extents.	
This result underscores intra-family differences, which 
preclude	 simple	 extrapolations.	 More	 than	 one	 bio-
chemical	route	can	explain	this	result.	In	principle,	ei-
ther the reduced Gal-1 presence may unmask sites, or a 
glycan remodelling may let cells reach the same end 
point. Such shifts in the glycome can be revealed by the 
same technical approach. Among the glycan character-
istics	 examined	 by	 the	 14	 plant/fungal lectins, a de-
crease	of	 α2,6-sialylation	 (but	 not	 α2,3-sialylation)	 of	
N-glycans and an increase of non-sialylated core 1 di-
saccharide	 presentation	 (reactive	with	 PNA)	were	 de-
tected. Although the molecular mechanisms leading to 
manifestation of these alterations are presently unde-
fined	 (regulatory	 processes	 at	 the	 level	 of	 α2,6-si	a-
lyltransferase-I,	 of	 enzyme(s)	 in	 the	 pathway	of	 sialic	
acid biosynthesis or of both are candidates for remodel-
ling this aspect of N-glycosylation; affecting sialidase, 
core	1-specific	α2,3-sialyltransferases,	de novo synthe-
sis of the core 1 disaccharide or a combination the-
reof are possibilities for remodelling this aspect of 
O-glycosylation),	it	is	in	this	context	salient	to	note	that	
structural changes in both respects can favour binding of 
S. André et al.
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Gal-1,	-3	and	-7	(Wasano	and	Hirakawa,	1997; Ahmad 
et	al.,	2004;	André	et	al.,	2007;	Krzeminski	et	al.,	2011).	
Evidently, dynamic restructuring within the glycome 
can at least contribute to the effect measured by apply-
ing	labelled	Gal-1,	-3	and	-7.	
Looking	at	the	data	of	glycophenotyping	with	PNA/
jacalin, rather constant jacalin reactivity, as documented 
in	Fig.	7K,	L,	appears	to	argue	in	favour	of	a	shift	in	the	
population of core 1 O-glycans from the sialylated tri-
saccharide to the non-sialylated disaccharide by a siali-
dase-dependent reaction or by reduced core 1 disaccha-
ride	α2,3-sialylation	during	de novo synthesis. In both 
instances, the sum of jacalin-reactive core 1 di- and tri-
saccharides	stays	constant.	In	turn,	the	extent	of	PNA-	
-reactive disaccharide increases. Bringing modulation 
of sialidase activity into play, it is known to be the cause 
for enhanced Gal-1 binding on activated effector T cells 
and	on	neuroblastoma	(SK-N-MC)	cells	via	stimulated	
conversion of ganglioside GD1a to the Gal-1 counter-
receptor	GM1	(Kopitz	et	al.,	1998;	Wang	et	al.,	2009;	
Wu	et	al.,	2011;	Ledeen	et	al.,	2012).	Case	studies	on	
activated T cells with PNAhigh phenotype furnish prece-
dents for the de novo	 route	 (see	Amado	 et	 al.,	 2004	
and	references	 cited).	 Cell	 biologically,	 the	 increased	
PNA reactivity was achieved in colon adenocarcinoma 
(HT-29)	cells	by	over-expressing	sialidase	NEU1,	β4-in-
tegrin as major target glycoprotein of PNA in lectin 
blots, and this parameter change went along with sup-
pressed cell migration, invasion and adhesion in vitro 
(Uemura	et	al.,	2009).	The	selective	nature	of	these	two	
Rac1-dependent changes on N- and O-glycosylation is 
underlined by the series of monitored features found to 
be unaffected such as the N-glycan core substitutions.
In summary, the presented data disclosed a marked 
influence	of	the	Rac1	expression	level	on	distinct	galec-
tins and particular characteristics of the cell surface gly-
cophenotype. Thus, affecting galectin/glycan-mediated 
interactions and signalling as well as enabling further 
functional consequences by changes of glycosylation 
should now be added to the potential effector mecha-
nisms of Rac1, giving further work a clear direction. 
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